22UA:ETR
BioNTech SE - ADR
€83.70
arrow_downward
-2.62%(-2.25) 1D
Sep 18, 5:35:57 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€86.80
High
€87.50
Low
€83.50
Mkt. cap
24.13B
Avg. vol.
52.51K
Volume
25.25K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
Open
€86.80
High
€87.50
Low
€83.50
Mkt. cap
24.13B
Avg. vol.
52.51K
Volume
25.25K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
News stories
From web sources and news partners
Kalkine Media
·
1 hour ago
BioNTech CEO Ugur Sahin Executes Sale of 64,000 Shares Under 10b5-1 Plan
TipRanks
·
3 hours ago
BioNTech Names KPMG as New Independent Auditor for 2027 Financial Year
Stock Titan
·
3 hours ago
BioNTech (NASDAQ: BNTX) CEO keeps 39.2M-share stake after sale
AD HOC NEWS
·
13 hours ago
BioNTech stock gains on fresh lung cancer data
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR